Sanofi Bets Up to $1.53B in Hong Kong Immuno Pact, Adding to String of Deals

By /

Sanofi will gain global exclusive rights over rovadicitinib, an oral JAK/ROCK blocker that has anti-inflammatory and anti-fibrotic effects.

Scroll to Top